ATE549417T1 - Diagnoseverfahren für osteoarthritis - Google Patents

Diagnoseverfahren für osteoarthritis

Info

Publication number
ATE549417T1
ATE549417T1 AT07816051T AT07816051T ATE549417T1 AT E549417 T1 ATE549417 T1 AT E549417T1 AT 07816051 T AT07816051 T AT 07816051T AT 07816051 T AT07816051 T AT 07816051T AT E549417 T1 ATE549417 T1 AT E549417T1
Authority
AT
Austria
Prior art keywords
osteoarthritis
risk
subject
cellular level
nuclear
Prior art date
Application number
AT07816051T
Other languages
English (en)
Inventor
Alain Moreau
Original Assignee
Chu Sainte Justine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chu Sainte Justine filed Critical Chu Sainte Justine
Application granted granted Critical
Publication of ATE549417T1 publication Critical patent/ATE549417T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • G01N2333/4704Inhibitors; Supressors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • G01N2333/4706Regulators; Modulating activity stimulating, promoting or activating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/105Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
AT07816051T 2006-10-25 2007-10-25 Diagnoseverfahren für osteoarthritis ATE549417T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85407706P 2006-10-25 2006-10-25
PCT/CA2007/001901 WO2008049225A1 (en) 2006-10-25 2007-10-25 Methods for diagnosing osteoarthritis

Publications (1)

Publication Number Publication Date
ATE549417T1 true ATE549417T1 (de) 2012-03-15

Family

ID=39324072

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07816051T ATE549417T1 (de) 2006-10-25 2007-10-25 Diagnoseverfahren für osteoarthritis

Country Status (7)

Country Link
US (3) US20100028882A1 (de)
EP (1) EP2089546B1 (de)
AT (1) ATE549417T1 (de)
AU (1) AU2007308715B2 (de)
CA (1) CA2703124C (de)
ES (1) ES2386916T3 (de)
WO (1) WO2008049225A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2386916T3 (es) 2006-10-25 2012-09-05 Chu Sainte-Justine Métodos de diagnosticar osteoartritis
MX2011008138A (es) 2009-02-02 2012-05-08 Nestec Sa Metodos para diagnosticar falla de articulacion inminente.
WO2013053065A1 (en) * 2011-10-14 2013-04-18 Hôpital Ste-Justine Methods and kits for diagnosing and/or prognosing osteoarthritis
CN105940101A (zh) 2013-11-21 2016-09-14 纪念斯隆-凯特琳癌症中心 由人多能干细胞特化功能性颅基板衍生物
CN115992240A (zh) * 2022-10-28 2023-04-21 中山大学附属第三医院 E2f转录因子2作为治疗靶点在制备预防和/或治疗多发性骨髓瘤的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271294A (ja) * 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするdna
US6127158A (en) 1994-12-07 2000-10-03 President And Fellows Of Harvard College Ubiquitin conjugating enzymes
AU2002230997A1 (en) 2000-12-15 2002-06-24 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
US20060094056A1 (en) * 2003-09-15 2006-05-04 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose treat, and evaluate inflammatory and autoimmune diseases
WO2006089268A2 (en) 2005-02-18 2006-08-24 The University Of North Carolina At Chapel Hill Gene and cognate protein profiles and methods to determine connective tissue markers in normal and pathologic conditions
EP1941057A4 (de) 2005-10-07 2009-11-11 Baylor Res Inst Diagnose des systemischen ausbruchs juveniler idiopathischer arthritis über blutleukozyten-mikroarrayanalyse
ES2386916T3 (es) 2006-10-25 2012-09-05 Chu Sainte-Justine Métodos de diagnosticar osteoartritis
CN103035712B (zh) 2011-10-09 2015-10-14 中国科学院微电子研究所 半导体器件及其制造方法
WO2013053065A1 (en) 2011-10-14 2013-04-18 Hôpital Ste-Justine Methods and kits for diagnosing and/or prognosing osteoarthritis

Also Published As

Publication number Publication date
US10324095B2 (en) 2019-06-18
AU2007308715A1 (en) 2008-05-02
WO2008049225A8 (en) 2008-07-03
WO2008049225A1 (en) 2008-05-02
CA2703124C (en) 2017-06-13
US20160299155A1 (en) 2016-10-13
US20150153362A1 (en) 2015-06-04
CA2703124A1 (en) 2008-05-02
US20100028882A1 (en) 2010-02-04
ES2386916T3 (es) 2012-09-05
EP2089546B1 (de) 2012-03-14
EP2089546A1 (de) 2009-08-19
EP2089546A4 (de) 2010-03-03
AU2007308715B2 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
Vučić Lovrenčić et al. Diagnostic challenges of diabetic kidney disease
Hu et al. Urinary mitochondrial DNA levels identify acute kidney injury in surgical critical illness patients
RU2009139295A (ru) Биомаркеры и биомаркерные признаки почечной сохранности, обладающие предсказательной силой, для использования в мониторинге состояния почек
EA201290711A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
BRPI0707645B8 (pt) métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano
GB2497477A (en) Determining the quantity of a taggant in a liquid sample
NZ625423A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ630277A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
NZ608384A (en) Biomarkers of renal injury
NO20081374L (no) Analyser og fremgangsmater som benytter biomarkorer
BR112012011230A2 (pt) fatores de risco e previsão de infarto do miocárdio
EA201490384A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
WO2010005991A3 (en) Circulating tumor and tumor stem cell detection using genomic specific probes
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Chatziharalambous et al. Analytical performance of ELISA assays in urine: one more bottleneck towards biomarker validation and clinical implementation
ATE504002T1 (de) Erkennung und vorhersage von frühgeburten
EA201290056A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
WO2010076556A3 (en) A conductivity measurement cell
Liu et al. Downregulation of miR-574-5p inhibits HK-2 cell viability and predicts the onset of acute kidney injury in sepsis patients
NZ628085A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Luk et al. Urinary biomarkers for the prediction of reversibility in acute‐on‐chronic renal failure
EP2089546A4 (de) Diagnoseverfahren für osteoarthritis